Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

glaucoma

  • Home
  • glaucoma
Intraoperative Intravitreal Bevacizumab Extended Trabeculectomy Survival to 3 Years in a Randomized Trial
Posted innews Ophthalmology

Intraoperative Intravitreal Bevacizumab Extended Trabeculectomy Survival to 3 Years in a Randomized Trial

Posted by MedXY By MedXY 05/20/2026
A double-blind randomized trial found that a single intraoperative intravitreal bevacizumab injection improved 3-year trabeculectomy survival and reduced postoperative medication needs versus placebo.
Read More
Delayed Glaucoma Follow-Up Was Usually Not Linked to Visual Field Progression, but Longer Gaps May Matter in More Advanced Disease
Posted innews Ophthalmology Public Health

Delayed Glaucoma Follow-Up Was Usually Not Linked to Visual Field Progression, but Longer Gaps May Matter in More Advanced Disease

Posted by MedXY By MedXY 05/18/2026
In a large retrospective glaucoma cohort, delayed follow-up was common yet was not generally associated with visual field worsening, although longer delays appeared more consequential in eyes with worse baseline visual field loss.
Read More
Personalized Glaucoma Coaching Boosts Medication Adherence by 20%: SEE Program Trial Results
Posted innews Ophthalmology

Personalized Glaucoma Coaching Boosts Medication Adherence by 20%: SEE Program Trial Results

Posted by MedXY By MedXY 04/23/2026
A 6-month personalized coaching program (SEE) significantly improved glaucoma medication adherence by 19.7% compared to standard education, reducing vision loss risk in a randomized trial of 235 patients.
Read More
Association of Deep Optic Nerve Head Structural Remodeling with Choroidal Microvasculature Dropout in Glaucoma with and without Myopia
Posted innews Ophthalmology

Association of Deep Optic Nerve Head Structural Remodeling with Choroidal Microvasculature Dropout in Glaucoma with and without Myopia

Posted by MedXY By MedXY 04/21/2026
Study reveals significant links between optic nerve head structural changes and choroidal microvascular dropout in glaucomatous eyes, particularly in myopia. Deep structural parameters like neural canal geometry strongly correlate with microvascular damage severity.
Read More
Microvascular Dropout and Parapapillary Atrophy Progression Predict Structural Optic Disc Damage in Glaucoma Suspects
Posted innews Ophthalmology

Microvascular Dropout and Parapapillary Atrophy Progression Predict Structural Optic Disc Damage in Glaucoma Suspects

Posted by MedXY By MedXY 03/30/2026
A 19-year retrospective study reveals that microvascular dropout and β-zone parapapillary atrophy progression are powerful independent predictors of structural optic disc damage in glaucoma suspects, even when visual fields remain stable.
Read More
Microvascular Dropout as a Potent Biomarker for Structural Progression in Glaucoma Suspects
Posted innews Ophthalmology

Microvascular Dropout as a Potent Biomarker for Structural Progression in Glaucoma Suspects

Posted by MedXY By MedXY 03/16/2026
A retrospective cohort study reveals that microvascular dropout (MvD) and β-zone parapapillary atrophy (PPA) progression are significant independent predictors of structural optic disc damage in glaucoma suspect eyes, identifying risk long before the onset of perimetric visual field loss.
Read More
Optimizing Glaucoma Management through Behavioral Intervention: Insights from the SEE Randomized Clinical Trial
Posted inClinical Updates news Ophthalmology

Optimizing Glaucoma Management through Behavioral Intervention: Insights from the SEE Randomized Clinical Trial

Posted by MedXY By MedXY 02/26/2026
The SEE randomized clinical trial demonstrates that a 6-month personalized coaching program using motivational interviewing significantly improves glaucoma medication adherence and reduces patient distress compared to standard education.
Read More
The 22 mm Hg Threshold: Does a Historical Cutoff Still Dictate Modern Glaucoma Management?
Posted innews Ophthalmology

The 22 mm Hg Threshold: Does a Historical Cutoff Still Dictate Modern Glaucoma Management?

Posted by MedXY By MedXY 01/17/2026
A multicenter cohort study of 1.8 million clinic encounters reveals that while clinicians view intraocular pressure as a continuous risk factor, the historical 22 mm Hg cutoff remains a significant psychological trigger for escalating glaucoma treatment.
Read More
Which Patients with Open-Angle Glaucoma Progress Faster? Key Prognostic Factors from a Cochrane Synthesis
Posted innews Ophthalmology

Which Patients with Open-Angle Glaucoma Progress Faster? Key Prognostic Factors from a Cochrane Synthesis

Posted by MedXY By MedXY 12/15/2025
A Cochrane review of 22 cohort studies (6,082 patients) found bilateral disease, disc haemorrhage, female sex, and active treatment have the most consistent associations with visual-field progression in open-angle glaucoma, but overall evidence quality is limited.
Read More
Five-Year Visual Outcomes After Lensectomy for Childhood Traumatic Cataract: Modest Vision Gains but High Rates of Visual Axis Opacification in Pseudophakia
Posted innews Ophthalmology Pediatrics

Five-Year Visual Outcomes After Lensectomy for Childhood Traumatic Cataract: Modest Vision Gains but High Rates of Visual Axis Opacification in Pseudophakia

Posted by MedXY By MedXY 11/25/2025
A prospective PEDIG cohort found modest long-term vision after lensectomy for pediatric traumatic cataract, low 5-year glaucoma prevalence, and high 5-year surgery rates for visual axis opacification in pseudophakic eyes, especially without anterior vitrectomy.
Read More
Nonmedical Factors Impacting Quality of Care in Newly Diagnosed Primary Open-Angle Glaucoma Patients
Posted inClinical Updates news Ophthalmology Specialties

Nonmedical Factors Impacting Quality of Care in Newly Diagnosed Primary Open-Angle Glaucoma Patients

Posted by MedXY By MedXY 09/28/2025
This study reveals that socioeconomic status, residential location, and household composition significantly affect treatment outcomes and follow-up in newly diagnosed POAG patients, highlighting the need for targeted strategies to improve glaucoma care equity.
Read More
Deep Learning Prediction of Retinal Nerve Fiber Layer Thickness as a Novel Risk Biomarker for Glaucoma in Ocular Hypertension
Posted inAI news Ophthalmology Specialties

Deep Learning Prediction of Retinal Nerve Fiber Layer Thickness as a Novel Risk Biomarker for Glaucoma in Ocular Hypertension

Posted by MedXY By MedXY 09/12/2025
A novel deep learning model predicted retinal nerve fiber layer thickness from optic disc photos, enabling risk stratification for primary open-angle glaucoma in ocular hypertension patients, with baseline and longitudinal changes strongly correlated with disease conversion.
Read More
Deep Learning Predicts Glaucoma Risk via Retinal Nerve Fiber Layer Thickness from Ocular Hypertension Photographs
Posted inAI Ophthalmology Specialties

Deep Learning Predicts Glaucoma Risk via Retinal Nerve Fiber Layer Thickness from Ocular Hypertension Photographs

Posted by MedXY By MedXY 09/12/2025
Deep learning models predicting RNFL thickness from optic disc photographs can identify ocular hypertension patients at higher risk for primary open-angle glaucoma, enhancing early risk assessment and monitoring disease progression.
Read More
  • Restoring Physiology After Upper Extremity Amputation: What the First Human AMI Reconstruction Experience Suggests
  • Earlier ADHD Diagnosis May Mark a Better Educational Trajectory: What a Finnish Registry Study Found
  • When the ICU Trauma Lingers: How Family PTSD Symptoms Build Across the Critical Illness Journey
  • A New Bedside Twist on Passive Leg Raising: PPV Change Predicts Fluid Responsiveness During Pressure Support Ventilation
  • When Language Becomes a Safety Risk: English Proficiency and Hospital Restraint Practices
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in